Asia-Pacific Melanoma Diagnostics and therapeutic market - segmented by type of cancer and geography (2016 - 2021)

  • ID: 3784733
  • Report
  • 78 pages
  • Mordor Intelligence
1 of 4

FEATURED COMPANIES

  • Abbott Diagnostics
  • AstraZeneca
  • Eli Lilly
  • Merck
  • Pfizer
  • Roche
  • MORE
The Asia-Pacific melanoma diagnostics and therapeutics market was valued at USD 532 million in 2015 and is expected to reach USD 1,172 million by 2020.

Melanoma is one of the serious types of skin cancer that develops from pigment-containing cells called melanocytes. The market for melanoma diagnostics and therapeutics is increasing at a significant rate due to an increase in the prevalence of melanoma and improvement in healthcare facilities. In addition, government initiatives and technical advancements boost the market growth.

The market for melanoma can be segmented based on:

Types
- Superficial spreading melanoma
- Nodular melanoma
- Lentigno maligna melanoma
- Acral lentiginous melanoma
- Amelanotic melanoma
- Others
- Cutaneous malignant melanoma
- Melanoma of vulva
- Vaginal melanoma or melanoma of black passage
- Cancer Stage
- Stage 0
- Stage I
- Stage II
- Stage III
- Stage IV
- Diagnosis
- Dermatoscopy
- Sentinel lymph node biopsy
- X-rays
- Blood tests
- CT scan
- Ultrasound
- Treatment
- Treatment for early stage melanoma
- Surgery (Excision and Mohs surgery)
- Treatment for advanced stage melanoma
- Chemotherapy
- Biological therapy
- Radiotherapy
- Targeted therapy
- Immune therapy
- Surgery(Lymphadenectomy)
- Geographical regions

The Asia-Pacific countries, namely Japan, China and India, are expected to be the fastest-growing melanoma diagnostics and therapeutics markets.

Abbott Diagnostics, Agilent Technologies, Roche, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Sanofi, Qiagen N.V. Company and Teva Pharmaceuticals to name a few, are the key players of this market.

Drivers

- Increase in melanoma incident cases
- Approval and uptake of premium-priced products
- Effective immunotherapies
- Label extension of current therapies into the new settings
- Government initiatives

Restraints

- Lack of awareness in some developing regions
- High cost associated with the therapy
- Economic crisis
- Regulatory issues

Please note: As this product is updated at the time of order, dispatch will be 72 hours from the date the order and full payment is received
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott Diagnostics
  • AstraZeneca
  • Eli Lilly
  • Merck
  • Pfizer
  • Roche
  • MORE
1. Introduction
1.1 Report Description
1.2 Research Methodology
2. Executive Summary
3. Market Overview
3.1 Market Definition
3.2 Market Drivers
3.2.1 Increasing incidences of Melanoma cases
3.2.2 The approval and uptake of premium-priced products
3.2.3 Effective immunotherapies
3.2.4 Label extension of current therapies into the new settings
3.2.5 Government initiatives
3.3 Market restraints
3.3.1 Lack of awareness in some developing regions
3.3.2 High cost associated with the therapy
3.3.3 Economic crisis
3.3.4 Regulatory issues
3.4 Market Opportunitites
3.5 Market Threats
4. Porters Five Force Analysis
4.1 Bargaining Power of suppliers
4.2 Bargaining power of buyers
4.3 Degree of competition
4.4 Threat of substitution
4.5 Threat of new entrants
5. Market Segmentation
5.1 By Cancer Type
5.1.1 Superficial spreading melanoma
5.1.2 Nodular melanoma
5.1.3 Lentigno maligna melanoma
5.1.4 Acral lentiginous melanoma
5.1.5 Amelanotic melanoma
5.1.6 Others
5.1.6.1 Cutaneous malignant melanoma
5.1.6.2 Melanoma of vulva
5.1.6.3 Vaginal melanoma or melanoma of black passage
5.2 By Cancer stage
5.2.1 Stage 0
5.2.1 Stage I
5.2.1 Stage II
5.2.1 Stage III
5.2.1 Stage IV
5.3 By Diagnosis
5.3.1 Dermatoscopy
5.3.2 Sentinel lymph node Biopsy
5.3.3 Blood Tests
5.3.4 X-rays
5.3.5 Ultrasound
5.3.6 CT Scan
5.4 ByTreatment
5.4.1 For early melanoma
5.4.1.1 Surgery
5.4.1.1.1 Excision
5.4.1.1.2 Mohs surgery
5.4.2 For advanced melanoma
5.4.2.1 Chemotherapy
5.4.2.2 Biological therapy
5.4.2.3 Radiotherapy
5.4.2.4 Targeted therapy,
5.4.2.5 Immune therapy
5.4.2.6 Surgery
5.4.2.6.1 Lymphadenectomy
5.5 By Geography
5.5.1 Asia-Pacific
5.5.1.1 India
5.5.1.2 China
5.5.1.3 Japan
5.5.1.4 Singapore
5.5.1.5 Rest of Asia Pacific
6. Competitive Landscape
7. Company Profiles
7.1 Abbott Diagnostics
7.2 Agilent Technologies
7.3 Roche
7.4 GlaxoSmithKline
7.5 AstraZeneca
7.6 Bristol-Myers Squibb
7.7 Eli Lilly
7.8 Merck
7.9 Novartis
7.10 Pfizer
7.11 Sanofi
7.12 Qiagen N.V. Company
7.13 Teva Pharmaceuticals
8. Appendix
8.1 Abbrevations
8.3 Bibliography
8.4 Disclaimer
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Abbott Diagnostics
Agilent Technologies
Roche
GlaxoSmithKline
AstraZeneca
Bristol-Myer Squibb
Eli Lilly
Merck
Novartis
Pfizer
Sanofi
Qiagen N. V. Company
Teva Pharmaceuticals
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll